Semax vs PE-22-28: What’s the Difference?
The main difference between Semax and PE-22-28 is mechanism: Semax is studied for cognitive enhancement research — Synthetic peptide analog of ACTH. PE-22-28 is studied for trek-1 potassium channel antidepressant research — Selectively inhibits the TREK-1 two-pore potassium channel, enhancing serotonergic transmission in mood-relevant circuits.
Stimulating nootropic vs antidepressant-oriented peptide.
Key differences between Semax and PE-22-28
- •Mechanism: Semax — Synthetic peptide analog of ACTH. PE-22-28 — Selectively inhibits the TREK-1 two-pore potassium channel, enhancing serotonergic transmission in mood-relevant circuits.
- •Primary research focus: Semax is studied for cognitive enhancement research; PE-22-28 is studied for trek-1 potassium channel antidepressant research.
- •Overlap: the two compounds share brain & cognitive support.
- •Discussion context: Semax is most often discussed alongside cognitive enhancement research, while PE-22-28 centres on trek-1 potassium channel antidepressant research.
| Attribute | Semax ACTH(4-10) analog | PE-22-28 Spadin analog |
|---|---|---|
| Category | Brain & Cognitive Support | Brain & Cognitive Support |
| Best known for | Cognitive enhancement research | TREK-1 potassium channel antidepressant research |
| Mechanism of action | Synthetic peptide analog of ACTH. Elevates BDNF. Acute focus and memory effects. | Selectively inhibits the TREK-1 two-pore potassium channel, enhancing serotonergic transmission in mood-relevant circuits. |
| Human research | Limited | Not catalogued |
| Animal research | Moderate | Not catalogued |
| Mechanistic research | Emerging | Not catalogued |
| Study cadence cited | Daily, multiple administrations | — |
| In plain English | Semax is the focus peptide. Researchers study how it boosts BDNF and NGF — the brain's growth and repair factors. | It blocks a brain potassium channel involved in mood regulation, aiming for fast-acting antidepressant effects. |
| How it works | Upregulates BDNF and NGF expression, modulates dopamine and serotonin, and inhibits enkephalin breakdown. | Selectively inhibits the TREK-1 two-pore potassium channel, enhancing serotonergic transmission in mood-relevant circuits. |
| Researchers study | Cognitive function, ischemic stroke recovery, ADHD, and neuroprotection. | Depression, anxiety, and stress-resilience models. |
| Internet discussion | Stacked with Selank as the canonical Russian nootropic combo. | Discussed in advanced nootropic and mood research circles. |
Mechanism and research evidence, side by side
How Semax and PE-22-28 differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Semax
Synthetic peptide analog of ACTH. Elevates BDNF. Acute focus and memory effects.
- CNS receptor systems (melanocortin, BDNF, GABAergic or sleep-regulating)
- Neurotransmitter and neurotrophic signalling
- Cognition, mood, sleep and libido research endpoints
- Human research
- Limited
- Animal research
- Moderate
- Mechanistic research
- Emerging
Focus, memory, cognitive enhancement, neuroprotection
Semax
Cognitive enhancement research
Semax is the focus peptide. Researchers study how it boosts BDNF and NGF — the brain's growth and repair factors.
Upregulates BDNF and NGF expression, modulates dopamine and serotonin, and inhibits enkephalin breakdown.
Cognitive function, ischemic stroke recovery, ADHD, and neuroprotection.
Stacked with Selank as the canonical Russian nootropic combo.
Semax is a nootropic peptide researched for BDNF/NGF upregulation and cognitive support.
PE-22-28
TREK-1 potassium channel antidepressant research
It blocks a brain potassium channel involved in mood regulation, aiming for fast-acting antidepressant effects.
Selectively inhibits the TREK-1 two-pore potassium channel, enhancing serotonergic transmission in mood-relevant circuits.
Depression, anxiety, and stress-resilience models.
Discussed in advanced nootropic and mood research circles.
PE-22-28 is a spadin-derived TREK-1 blocker researched as a fast-acting antidepressant peptide.